Plain-English translation of NCT05878730 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers want to understand why lithium works well for some people with bipolar disorder type 1 but not for others. This study will compare levels of melatonin and related proteins in blood and urine samples from people who respond well to lithium with those who don't respond as well, looking for biological differences that might explain the difference in treatment response.
Lithium is an important mood-stabilizing medication for bipolar disorder, but doctors can't predict in advance who will benefit from it and who won't. By finding biological markers linked to good response, researchers hope to eventually help doctors choose the right treatment for each patient more quickly.
You likely qualify if…
You likely don't qualify if…
You would have two main visits over about a month. At your first visit, you'll answer questions about your mood, sleep, and medical history, and receive instructions for collecting urine at home overnight and keeping a sleep diary for one week. At your second visit about a week to a month later, you'll return your urine sample and sleep diary, and provide a blood sample so researchers can measure melatonin levels and related proteins.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
France